Huntington's Disease: An Immune Perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

1. Extracellular Vesicles and Exosomes as Biomarkers in Huntington's Disease: Uncovering Pathogenic Insights and Pioneering Therapies.Molecular neurobiology · 2026
   Review
2. Reprogramming brain-resident macrophages: from disease drivers to therapeutic allies in neurological disorders.Frontiers in cellular neuroscience · 2026
   Review
3. Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.Acta pharmacologica Sinica · 2025
   Review
4. The microbiota-gut-brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets.The FEBS journal · 2025
   Review
5. Pathogenic Huntingtin aggregates alter actin organization and cellular stiffness resulting in stalled clathrin-mediated endocytosis.eLife · 2024
   Article
6. The complement system in neurodegenerative and inflammatory diseases of the central nervous system.Frontiers in neurology · 2024
   Review
7. Gut Microbiota in Autophagy Regulation: New Therapeutic Perspective in Neurodegeneration.Life (Basel, Switzerland) · 2023
   Review
8. The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases.Frontiers in aging · 2023
   Review
9. A New Perspective on Huntington's Disease: How a Neurological Disorder Influences the Peripheral Tissues.International journal of molecular sciences · 2022
   Review
10. Aberrant Complement System Activation in Neurological Disorders.International journal of molecular sciences · 2021
    Review
11. Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.Immunology · 2021
    Review
12. Minocycline plus N-acteylcysteine induces remyelination, synergistically protects oligodendrocytes and modifies neuroinflammation in a rat model of mild traumatic brain injury.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Article
13. An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Archives of toxicology · 2018
    Review
14. Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model.Biomarker research · 2013
    Article
15. β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.Journal of Huntington's disease · 2013
    Article
16. The role of the immune system in Huntington's disease.Clinical & developmental immunology · 2013
    Review
17. Creatine supplementation improves neural progenitor cell survival in Huntington's disease.Brain circulation
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 3 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract